Evidence map›Paper›PMID 30127521›Full record

ArticlePediatric research2018

Menkes disease: Oral administration of glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) rescues the macular mouse.

Mitsutoshi Munakata, Hiroko Kodama, Norihiko Tani, Kazuhiko Kimura, Hideyo Takahashi, Kazuo Maruyama, Yoshimasa Sakamoto, Shigeo Kure

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mitsutoshi MunakataDepartment of Pediatrics, Tohoku University School of Medicine, Sendai, Japan. m-munakata@umin.ac.jp.
Hiroko KodamaDepartment of Pediatrics, Teikyo University School of Medicine, Sendai, Japan.
Norihiko TaniFaculty of Pharma Sciences, Teikyo University, Tokyo, Japan.
Kazuhiko KimuraDepartment of Farm Management, School of Food, Agricultural and Environmental Sciences, Miyagi University, Sendai, Japan.
Hideyo TakahashiFaculty of Pharma Sciences, Teikyo University, Tokyo, Japan.
Kazuo MaruyamaFaculty of Pharma Sciences, Teikyo University, Tokyo, Japan.
Yoshimasa SakamotoCentral Experimental Animal Center, Teikyo University, Tokyo, Japan.
Shigeo KureDepartment of Pediatrics, Tohoku University School of Medicine, Sendai, Japan.
Teikyo University · JPTohoku University · JPMiyagi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMenkes disease is a copper metabolism disorder caused by mutations in ATP7A, a copper-transporting P-type ATPase. In this study, oral copper supplementation via glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) (CuGTSM), a lipophilic copper complex, was investigated in male hemizygous macular (Mo

methodsCuGTSM was administered by oral gavage on postnatal days 5, 8, 11, 17, 23, and 32. The copper levels in the organs and serum, copper-dependent enzyme activities in the brain, and ceruloplasmin (Cp) activity in the serum were measured at 15 days and 3 and 8 months of age. Histological analysis of the intestines and the rotarod test were also performed.

resultsCuGTSM treatment extended the lifespan of Mo

conclusionOral administration of CuGTSM extended the lifespan of Mo

Indexed as

Administration, OralAnimalsCoordination ComplexesCopperCopper-Transporting ATPasesDisease Models, AnimalDose-Response Relationship, DrugMaleMenkes Kinky Hair SyndromeMiceMutationSurvival RateThiosemicarbazonesTissue DistributionWeight GainAtp7a protein, mouseCoordination ComplexesCopperCopper-Transporting ATPasesglyoxal-bis(4-methylthiosemicarbazonato)copper(II)Thiosemicarbazones

Identifiers

PMID30127521
OpenAlexW2883273030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.